| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Oleanolic acid hemiphthalate disodium salt targets inflammatory pathways as an anti-inflammatory agent. As a derivative of oleanolic acid, a naturally occurring pentacyclic triterpenoid with known anti-inflammatory and hepatoprotective properties, this compound is used to study inflammation and related therapeutic applications.
|
|---|---|
| ln Vitro |
Oleanolic acid hemiphthalate disodium salt demonstrates in vitro anti-inflammatory activity. The compound shows potential anti-ulcer activities. As a hemiphthalate derivative, it may offer improved solubility and pharmaceutical properties compared to the parent compound. Purity is typically >98%.
|
| ln Vivo |
In vivo, Oleanolic acid hemiphthalate disodium salt is used as a research tool to study anti-inflammatory and anti-ulcer effects. Further in vivo studies would be required to fully characterize its systemic activity, therapeutic potential, and mechanism of action in animal models of inflammation and ulcer disease.
|
| Enzyme Assay |
In vitro anti-inflammatory assays for Oleanolic acid hemiphthalate disodium salt typically involve treating inflammatory cells (e.g., macrophages, microglia) with varying concentrations of the compound, followed by stimulation with pro-inflammatory agents (e.g., LPS). Readouts include measurement of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) by ELISA, nitric oxide production, and assessment of NF-kappaB pathway activation.
|
| Cell Assay |
In vitro cellular assays for Oleanolic acid hemiphthalate disodium salt involve treating relevant cell lines (e.g., macrophages, epithelial cells) with varying concentrations of the compound (typically 0.1-100 microM range) for 24-72 hours. Readouts include cell viability, assessment of inflammatory markers by qPCR or ELISA, and evaluation of antioxidant and cytoprotective effects.
|
| Animal Protocol |
In vivo animal studies for Oleanolic acid hemiphthalate disodium salt would typically employ rodent models of inflammation (e.g., carrageenan-induced paw edema, DSS-induced colitis) or ulcer disease. Animals would be administered the compound via appropriate routes at various doses. Endpoints include assessment of inflammatory markers, tissue histology, and disease severity scores.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Oleanolic acid hemiphthalate disodium salt are characteristic of triterpenoid derivatives. The disodium salt form may enhance aqueous solubility. PK parameters including half-life, Cmax, Tmax, and AUC would be determined via LC-MS/MS analysis following administration in appropriate animal models. The compound is typically stored as a powder at -20degC for up to 3 years.
|
| Toxicity/Toxicokinetics |
Oleanolic acid hemiphthalate disodium salt is a research-grade compound for laboratory use only. As with all research chemicals, standard safety precautions should be observed during handling including appropriate PPE and work in a fume hood. The compound is not intended for human therapeutic use.
|
| Additional Infomation |
Oleanolic acid hemiphthalate disodium salt (CAS# 168770-31-8) is an anti-inflammatory agent and hemiphthalate derivative of oleanolic acid with potential anti-ulcer activities. It is used as a research tool to study inflammation and related therapeutic applications. The compound is not approved for clinical use. It is typically stored at -20degC.
|
| Molecular Formula |
C38H50NA2O6
|
|---|---|
| Molecular Weight |
648.7796
|
| Exact Mass |
648.34
|
| CAS # |
168770-31-8
|
| PubChem CID |
138454806
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
46
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)[O-])C)C)(C)C)OC(=O)C6=CC=CC=C6C(=O)[O-].[Na+].[Na+]
|
| InChi Key |
YBXPMGGHNXZAJS-IAYBDFNWSA-L
|
| InChi Code |
InChI=1S/C38H52O6.2Na/c1-33(2)18-20-38(32(42)43)21-19-36(6)25(26(38)22-33)12-13-28-35(5)16-15-29(34(3,4)27(35)14-17-37(28,36)7)44-31(41)24-11-9-8-10-23(24)30(39)40;;/h8-12,26-29H,13-22H2,1-7H3,(H,39,40)(H,42,43);;/q;2*+1/p-2/t26-,27-,28+,29-,35-,36+,37+,38-;;/m0../s1
|
| Chemical Name |
disodium;(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-(2-carboxylatobenzoyl)oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~32.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5414 mL | 7.7068 mL | 15.4135 mL | |
| 5 mM | 0.3083 mL | 1.5414 mL | 3.0827 mL | |
| 10 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
